We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05408312
Recruitment Status : Active, not recruiting
First Posted : June 7, 2022
Last Update Posted : July 22, 2022
Sponsor:
Collaborators:
Lanzhou Institute of Biological Products Co., Ltd
Beijing Institute of Biological Products Co Ltd.
Information provided by (Responsible Party):
National Vaccine and Serum Institute, China

Tracking Information
First Submitted Date  ICMJE June 5, 2022
First Posted Date  ICMJE June 7, 2022
Last Update Posted Date July 22, 2022
Actual Study Start Date  ICMJE June 18, 2022
Estimated Primary Completion Date December 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 5, 2022)
  • The incidence rate of any adverse reactions/events [ Time Frame: within 30 minutes after vaccination ]
  • The incidence severity of any adverse reactions/events [ Time Frame: within 30 minutes after vaccination ]
  • the incidence of abnormal blood biochemistry, blood routine, blood coagulation function and urine routine [ Time Frame: on the 4th day after each dose of vaccination ]
  • The incidence rate of solicited adverse reactions/events [ Time Frame: within 0-7 days after vaccination ]
  • The incidence severity of solicited adverse reactions/events [ Time Frame: within 0-7 days after vaccination ]
  • The incidence rate of solicited adverse reactions/events [ Time Frame: within 8-30 days after vaccination ]
  • The incidence severity of solicited adverse reactions/events [ Time Frame: within 8-30 days after vaccination ]
  • Incidence of adverse events leading to withdrawal [ Time Frame: within 8-30 days after vaccination ]
  • Severity of adverse events leading to withdrawal [ Time Frame: within 8-30 days after vaccination ]
  • The incidence of SAE observed [ Time Frame: up to 12 months after full course of immunization ]
  • The incidence of AESI observed [ Time Frame: up to 12 months after full course of immunization ]
  • Neutralizing antibody level against SARS-CoV-2 GMT [ Time Frame: Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization ]
  • Neutralizing antibody level against SARS-CoV-2 IgG antibody GMC [ Time Frame: Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization ]
  • Neutralizing antibody level against SARS-CoV-2 positive rate [ Time Frame: Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization ]
  • Neutralizing antibody level against SARS-CoV-2 Positive conversion rate [ Time Frame: Day 15th, 30th, 90th, 180th, 270th, 360th after full course of immunization ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 5, 2022)
  • GMT of GEN2-Recombinant COVID-19 Vaccine (CHO cells, NVSI-06-08) against VOC in healthy people aged 18 and above [ Time Frame: after the full course of immunization ]
  • Cellular immune response level of subjects aged 18-59 [ Time Frame: Before the first vaccination , 15 days after the full course of immunization ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
Official Title  ICMJE Phase I Clinical Trial of Safety, Tolerance and Immunogenicity of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
Brief Summary

phase I study will evaluate the safety and tolerability of GEN2-Recombinant COVID-19 Vaccine (CHO cells) in healthy people aged 18 years and older.

A total of 234 subjects were enrolled, of which 126 were enrolled in the 18-59-year-old group, and were randomly assigned to receive experimental vaccine 1, experimental vaccine 2, experimental vaccine 3 and placebo in a ratio of 2:2:2:1; 60- A total of 54 people were enrolled in the 69-year-old and ≥70-year-old groups, and were randomly assigned to receive the experimental vaccine 1 and placebo according to the ratio of 2:1.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE COVID-19 Pneumonia
Intervention  ICMJE
  • Biological: Experimental Vaccine 1
    Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells,NVSI-06-08) in the deltoid muscle of the upper arm
  • Biological: Experimental Vaccine 2
    Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells,NVSI-06-08) in the deltoid muscle of the upper arm
  • Biological: Experimental Vaccine 3
    Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells,NVSI-06-08) in the deltoid muscle of the upper arm
  • Biological: placebo
    Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
Study Arms  ICMJE
  • Experimental: Experimental group 1
    Intervention: Biological: Experimental Vaccine 1
  • Experimental: Experimental group 2
    Intervention: Biological: Experimental Vaccine 2
  • Experimental: Experimental group 3
    Intervention: Biological: Experimental Vaccine 3
  • Placebo Comparator: placebo group
    Intervention: Biological: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: June 5, 2022)
234
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2023
Estimated Primary Completion Date December 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age range: healthy people aged 18 and above, who can provide legal identification;
  • No history of t SARS-CoV-2 vaccination;
  • Able to provide a negative nucleic acid test certificate for the new coronavirus within 48 hours;
  • Have the ability to understand (if illiterate, a fair witness is required to accompany the informed consent) research procedures, have informed consent, voluntarily sign the informed consent form, and be able to comply with the requirements of the clinical research protocol;
  • Inquire about medical history and physical examination, and the investigator judges that the health status is good;
  • Females of childbearing age (menarche to menopause) were not pregnant (negative urine pregnancy test) at enrollment, were not breastfeeding, and had no reproductive plans within the first 6 months after enrollment and took effective contraceptive measures; 2 weeks prior to enrollment have taken effective contraceptive measures;
  • Able and willing to complete the entire prescribed study plan throughout the study follow-up period.

Exclusion Criteria:

First-dose exclusion criteria:

  • Confirmed cases, suspected cases, asymptomatic infections, or close contacts of the above-mentioned groups of SARS-CoV-2 infection (check "China Disease Prevention and Control Information System");
  • Axillary body temperature ≥37.3℃ before vaccination;
  • Positive test for novel coronavirus antibody (IgG+IgM);
  • Have a history of SARS virus infection (self-report, on-site inquiry);
  • Fever (axillary temperature ≥37.3℃), dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, and dyspnea within 14 days before vaccination;
  • The test results of blood biochemistry, blood routine, urine routine and coagulation function-related indexes before vaccination are abnormal, which are beyond the reference value range and have clinically significant abnormalities;
  • Severe allergic reactions (such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioedema or abdominal pain) have occurred in the past;
  • Allergy to any component of the study vaccine (such as: aluminum, histidine, etc.);
  • Patients with convulsions, epilepsy, encephalopathy or other progressive neurological diseases (such as transverse myelitis, Guillain-Barre syndrome, demyelinating diseases, etc.), long-term history of alcohol and drug abuse, history of thyroidectomy, infectious diseases, mental illness medical or family history;
  • Known or suspected diseases include: severe respiratory disease, severe liver and kidney disease, severe cardiovascular disease, uncontrolled hypertension (systolic blood pressure ≥140mmHg, diastolic blood pressure ≥90mmHg), diabetic complications, malignant tumors, Various acute diseases, acute exacerbations of chronic diseases or severe chronic diseases;
  • Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
  • Thrombocytopenia, history of abnormal coagulation function (such as coagulation factor deficiency, coagulation disease);
  • Asplenia or splenectomy, functional asplenia caused by any circumstance;
  • Are receiving anti-TB (tuberculosis) treatment;
  • Received immune enhancement or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days);
  • Received live attenuated vaccine within 28 days before vaccination, and received other vaccines within 14 days before vaccination;
  • Received blood products within 3 months before vaccination;
  • Received other study drugs within 6 months before vaccination;
  • Planning to move before the end of the study or to be away from the local area for an extended period of time during a scheduled study visit;
  • The investigator judges other circumstances that are not suitable to participate in this clinical trial.

Exclusion criteria for second and third doses:

  • Positive urine pregnancy test;
  • Patients with abnormal conditions such as high fever (axillary temperature ≥39.0℃) for three days, convulsions, severe allergic reactions or any adverse reactions of the --Nervous system after the previous dose of vaccination;
  • Serious adverse reactions that are causally related to the previous dose of vaccination;
  • For those newly discovered or newly discovered after the previous dose of vaccine that do not meet the first-dose inclusion criteria or meet the first-dose exclusion criteria, the investigator will determine whether to continue participating in the study;
  • Other reasons for exclusion considered by the investigator.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05408312
Other Study ID Numbers  ICMJE CXSL2200156-Ⅰ
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party National Vaccine and Serum Institute, China
Original Responsible Party Same as current
Current Study Sponsor  ICMJE National Vaccine and Serum Institute, China
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Lanzhou Institute of Biological Products Co., Ltd
  • Beijing Institute of Biological Products Co Ltd.
Investigators  ICMJE Not Provided
PRS Account National Vaccine and Serum Institute, China
Verification Date July 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP